Patent intelligence · US
US 10369173
Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
Patent details — US 10369173
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 6, 2019
- Expiration
- Aug 1, 2039
- Applicant
- Capricor, Inc.
- Claims
- 20
- CPC classes
- A61K, A61K35/00, A61K35/34, A61P
Quick answer
US 10369173 (Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy) is held by Capricor, Inc.. Status: granted. Granted Aug 6, 2019. Expires Aug 1, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Capricor, Inc.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K35/00, A61K35/34, A61P, A61P9/00, A61P9/10
More from Capricor, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11801268
Methods of treating ocular inflammation and chemical injuries of the eye with extracellular vesicles
granted -
US 11759482
Methods and compositions for treating skeletal muscular dystrophy
granted -
US 10695293
Method of preventing or treating radiation-induced dermatitis with extracellular vesicles
granted -
US 9884076
Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
granted -
US 9623085
Chimeric natriuretic peptide compositions and methods of preparation
granted -
US 9616107
Therapy for kidney disease and/or heart failure
granted -
US 9314507
Methods of treatment of heart failure with natriuretic peptides
granted
Frequently asked questions
What is US patent 10369173?
US 10369173 (Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy) is held by Capricor, Inc.. Status: granted. Granted Aug 6, 2019. Expires Aug 1, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10369173?
Capricor, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 43 pharmaceutical patents for this assignee.
When does US 10369173 expire?
Our index shows an expiration date of Aug 1, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.